ONCOLOGY CLINICAL RESEARCH TRIALS -2009
A Randomized, double blind, Placebo-Controlled Phase III trial for
Postmenopausal Women with ER, PgR+ Advanced Breast CA.With
or without Inhibition of EGF & Her2 Growth Factor Receptors;
Neo-Adjuvant Phase III study comparing 16-18 wks of neoadjuvant Exemestane,
Letrozole. Or Anastrozole. Postmenopausal Stage II & III ER
A Randomized Phase III trial comparing three Chemotherapy
regimens with, without, Bevacizumab for Her2neu negative Breast
Resected by lumpectomy, tumor size < 3.9 cm, and no more than 3
positives nodes: Whole Breast irradiation or Partial breast
irradiation. Ineligible: > 50 yrs of age with DCIS; or with invasive
To determine the Efficacy of 5 yrs of Letrozole Compared to
Placebo in Pts. 5 yrs of Hormonal Therapy consisting of an AI or
Tamoxifen followed by an AI in prolonging DFS Postmenopause
Phase III study; Invasive CA; Her2 positive or negative: dose dense
Node positive regimens: AC (q 14 days, 4 vs. 6 cycles) Vs Taxol (4 vs. 6 cycles) +
ER/PR +; Node negative, Treatment type based on ONCOTYPE DX
Assay. Primary group Oncotype risk score 11-25 = Arm B
Hormonal Therapy or Arm C Chemo plus Hormonal Therapy.
Secondary Study Group Oncotype Risk Score < 11, = Arm A
Hormonal Therapy. Oncotype Risk Score > 25 = Arm D
Phase III Trial of Continuous Schedule AC + G Vs. q 2 wk schedule
AC, followed by Paclitaxel given either q 2 wks or weekly for 12
wks as Post-op Adjuvant Therapy in node + or High-Risk Node
Phase III Randomized trial of Anastrozole Vs. Anastrozole and
Fulvestrant as first line therapy for Postmenopausal women.
A Phase III Study of Bisphosphonates as Adjuvant therapy for
Primary Breast Cancer. No Mets. Resected. Primary Invasive, Must
Suppression of Ovarian Function Trial. Premenopausal (estradiol
E2) resected breast CA, ER+ or PR+, with or without chemo.
Remains Premenopausal post chemo (adj or neo). Node + (0; 1 or
A Phase III Randomized trial of FOLFOX vs. FOLFOX plus
Cetuximab (Erbitux) Stage III after curative resection. Node positive
A Phase III Randomized trial of adjuvant chemo radiation after
resection. Stomach or Gastro-Esophageal. Extension beyond
muscularis propria or nodule involvement:
Intergroup Randomized Phase III study of Post-Op Oxaliplatin, 5-
Fluorouracil & Leucovorin vs. Oxaliplatin, 5-Fluorouracil,
Leucovorin & Bevacizumab for Pt’s with Stage II or III Rectal Ca
receiving Pre-Op Chemo radiation. No Mets. < 12 cm from the anal
Stage II or III. < 12 cm from the anal verge. Pre-Op RT/
Capecitabine vs. Pre-op RT & CIVI 5 FU.
First line, FOLFOX or FOLFIRI plus Cetuximab or Bevacizumab or
A Randomized, Double-Blind Phase III trial of adjuvant Sunitinib
vs. Sorafenib vs. Placebo for resected Renal Cell Ca
Stage IB2, IIA, IIB, IIIB & IVA Cervical Ca limited to the Pelvis. A
Phase III Randomized trial of weekly Cisplatin & Radiation vs.
Cisplatin & Tirapazmine &Radiation. HEAD & LEUKEMIA CTSU/SWOG
A Phase III study of the addition of Gemtuzumab Ozogamicin
(Mylotarg) Induction therapy Vs. Standard Induction with
Daunomycin & Cytosine Arabinoside followed by Consolidation
and subsequent randomization to post-consolidation therapy with
Gemtuzumab Ozogamicin (Mylotarg) or no additional therapy for
Patients under age 61 with previously untreated De Novo AML
Cytogenetic study in leukemia patients. Patient must be registered
on another SWOG Leukemia study to be eligible.
Leukemia centralized reference laboratories & tissue repositories-
consent to perform cellular and molecular studies in leukemia
patients. Patient must be registered on another SWOG Leukemia
Phase III chemoprevention trial of Selenium Supplementation.
Molecular Epidemiology case series study of Non-Small Cell Lung
Ca in smoking & non-smoking women and men. Within 120 days of
LYMPHOM CTSU/CALGB
Phase III Randomized trial of R-CHOP vs. Dose adjusted EPOCH-R
with Molecular profiling in untreated De Novo diffuse large B-cell
A Phase III Randomized trial of Sentinel Lymphadenectomy and
complete lymph node dissection Vs. sentinel lymphadenectomy
alone. Cutaneous with molecular or histopathological evidence of
metastases in the sentinel node. Breslow thickness of 1.20 mm or
greater and Clark level III, or Clark level IV and V
Antidiarrhoeal activity of Rhus javanica ripen Department of Zoology, North-Eastern Hill University, Shillong 793 022, India Received 22 December 2002; accepted in revised form 5 August 2003 Abstract The antidiarrhoeal effects of the methanolic extract of Rhus javanica ripen fruits (MERJ)were investigated by employing four experimental models of diarrhoea in Swiss albino mice. MERJ tre
The American Chronic Pain Association Understanding Medical Devices for Pain Management INTRODUCTION Narrator (VO): If chronic pain is part of your life, you face many chal enges. It’s important that you take anactive role in your health care. When you do, you are meeting some of those chal enges head-on and reclaiming some of the control that pain can take away from you. One chal
ONCOLOGY CLINICAL RESEARCH TRIALS -2009